BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 26716506)

  • 1. p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.
    Bisaro B; Sciortino M; Colombo S; Camacho Leal MP; Costamagna A; Castellano I; Montemurro F; Rossi V; Valabrega G; Turco E; Defilippi P; Cabodi S
    Oncotarget; 2016 Jan; 7(4):4442-53. PubMed ID: 26716506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling ErbB2-p130Cas interaction to design new potential anticancer agents.
    Costamagna A; Rossi Sebastiano M; Natalini D; Simoni M; Valabrega G; Defilippi P; Visentin S; Ermondi G; Turco E; Caron G; Cabodi S
    Sci Rep; 2019 Feb; 9(1):3089. PubMed ID: 30816273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization.
    Li B; Meng Y; Zheng L; Zhang X; Tong Q; Tan W; Hu S; Li H; Chen Y; Song J; Zhang G; Zhao L; Zhang D; Hou S; Qian W; Guo Y
    Cancer Res; 2013 Nov; 73(21):6471-83. PubMed ID: 24046294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p130Cas promotes invasiveness of three-dimensional ErbB2-transformed mammary acinar structures by enhanced activation of mTOR/p70S6K and Rac1.
    Tornillo G; Bisaro B; Camacho-Leal Mdel P; Galiè M; Provero P; Di Stefano P; Turco E; Defilippi P; Cabodi S
    Eur J Cell Biol; 2011; 90(2-3):237-48. PubMed ID: 20961652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer.
    Nam S; Chang HR; Jung HR; Gim Y; Kim NY; Grailhe R; Seo HR; Park HS; Balch C; Lee J; Park I; Jung SY; Jeong KC; Powis G; Liang H; Lee ES; Ro J; Kim YH
    Cancer Lett; 2015 Jan; 356(2 Pt B):880-90. PubMed ID: 25449779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
    Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
    Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
    Kim WE; Serrero G
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4192-9. PubMed ID: 16857791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
    Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
    Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
    Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
    Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients.
    Cheng Y; Tao L; Xu J; Li Q; Yu J; Jin Y; Chen Q; Xu Z; Zou Q; Liu X
    Mol Carcinog; 2014 Sep; 53(9):686-97. PubMed ID: 23681900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2
    D'Alesio C; Bellese G; Gagliani MC; Aiello C; Grasselli E; Marcocci G; Bisio A; Tavella S; Daniele T; Cortese K; Castagnola P
    J Exp Clin Cancer Res; 2017 Nov; 36(1):154. PubMed ID: 29100552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological significance of β -tubulin isotype III gene expression in breast cancer patients.
    He Q; Peng B; Zhuang D; Xiao L; Zheng L; Fan Z; Zhu J; Xu B; Xu C; Zhao J; Wu L; Zhou P; Hou L; Yu F; Zhao G
    Cancer Biomark; 2015; 15(6):823-31. PubMed ID: 26406408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
    Huang X; Wang S; Lee CK; Yang X; Liu B
    Cancer Lett; 2011 Aug; 307(1):72-79. PubMed ID: 21497990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing Use of Neoadjuvant Treatment for T1 and T2 HER2-Positive Tumors.
    Al-Hilli Z; Boughey JC; Hoskin TL; Heins CN; Hieken TJ
    Ann Surg Oncol; 2015 Oct; 22(10):3369-75. PubMed ID: 26202564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
    Huang X; Gao L; Wang S; Lee CK; Ordentlich P; Liu B
    Cancer Res; 2009 Nov; 69(21):8403-11. PubMed ID: 19826038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.